

# Moderate to severe hidradenitis suppurativa – continuing authority application

## Online PBS Authorities



Requesting PBS Authorities online provides an immediate assessment in real time.

For more information and how to access the **Online PBS Authorities** system, go to [servicesaustralia.gov.au/hppbsauthorities](https://servicesaustralia.gov.au/hppbsauthorities)

## When to use this form

Use this form to apply for **continuing** PBS-subsidised adalimumab or secukinumab for patients with moderate to severe hidradenitis suppurativa.

## Important information

**Continuing** authority applications can be made in real time using the **Online PBS Authorities** system or in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Applications for **balance of supply** can be made in real time using the **Online PBS Authorities** system or by phone. Call 1800 700 270 Monday to Friday, 8 am to 5 pm, local time.

Under no circumstances will phone approvals be granted for moderate to severe hidradenitis suppurativa **continuing** authority applications.

The information in this form is correct at the time of publishing and may be subject to change.

## Continuing treatment

This form is **ONLY** for **continuing** treatment.

Applications for **subsequent continuing** treatment with PBS-subsidised biosimilar brands of adalimumab are **Authority Required (STREAMLINED)** and do not require authority approval from Services Australia for the listed quantity and repeats.

## Treatment specifics

The assessment of the patient's response to the course of treatment must be conducted within the time frame specified in the restriction. Where a demonstration of response is not conducted within the required time frame, the patient will be deemed to have failed treatment with that particular PBS-subsidised biological medicine.

A patient who has experienced a serious adverse reaction of a severity necessitating permanent treatment withdrawal is not considered to have failed treatment with that particular PBS-subsidised biological medicine.

## For more information

Go to [servicesaustralia.gov.au/healthprofessionals](https://servicesaustralia.gov.au/healthprofessionals)

# Moderate to severe hidradenitis suppurativa – continuing authority application

## Online PBS Authorities



You do not need to complete this form if you use the **Online PBS Authorities** system.

Go to [servicesaustralia.gov.au/hppbsauthorities](https://servicesaustralia.gov.au/hppbsauthorities)

## Patient's details

### 1 Medicare card number

Ref no.

or

Department of Veterans' Affairs card number

### 2 Family name

First given name

### 3 Date of birth (DD MM YYYY)

## Prescriber's details

### 4 Prescriber number

### 5 Family name

First given name

### 6 Business phone number (including area code)

Alternative phone number (including area code)

## Conditions and criteria

To qualify for PBS authority approval, the following conditions must be met.

### 7 Is the patient being treated by a dermatologist?

Yes ☐

No ☐

### 8 This application is for:

☐ adalimumab as

☐ the **first continuing** treatment

or

☐ the **subsequent continuing** treatment

or

☐ secukinumab continuing treatment

### 9 Has the patient previously received PBS-subsidised treatment with this drug for this condition?

Yes ☐

No ☐

### 10 Has the patient demonstrated a response to treatment with this drug for this condition by achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in an abscess and inflammatory nodule (AN) count compared to baseline with no increase in abscesses or draining fistulae?

Yes ☐

No ☐

### 11 Was the assessment of response conducted within the required time frame specified in the restriction?

Yes ☐

No ☐

## Checklist

### 12 The relevant attachments need to be provided with this form.

☐ Details of the proposed prescription(s).



MCA0PB219 2506

## Privacy notice

- 13** Personal information is protected by law (including the *Privacy Act 1988*) and is collected by Services Australia for the purposes of assessing and processing this authority application. Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or where it is required or authorised by law (including for the purpose of research or conducting investigations).

More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at [servicesaustralia.gov.au/privacypolicy](https://servicesaustralia.gov.au/privacypolicy)

## Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at [servicesaustralia.gov.au/hpos](https://servicesaustralia.gov.au/hpos)

### 14 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction
- the information I have provided in this form is complete and correct.

#### I understand that:


- giving false or misleading information is a serious offence.

☐ I have read, understood and agree to the above.

Date (DD MM YYYY) (you **must** date this declaration)

--	--	--	--	--	--	--	--	--	--

Prescriber's signature (**only** required if returning by post)


---

## Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

- **online** (no signature required), upload through HPOS at [servicesaustralia.gov.au/hpos](https://servicesaustralia.gov.au/hpos)
- **or**
- by post (signature required) to  
Services Australia  
Complex Drugs Programs  
Reply Paid 9826  
HOBART TAS 7001